SAB Biotherapeutics (SABSW) Stock Analysis & Winston Score

SAB Biotherapeutics is a clinical-stage biotechnology company that uses genetically engineered cattle to produce human antibodies. Instead of making antibodies in a lab or using human donors, the company modifies cows so their immune systems create large quantities of fully human antibodies when exposed to a disease target. These antibodies are then collected and developed into potential treatments for infectious diseases and other serious conditions. The company earns revenue primarily through government contracts and research grants rather than product sales, since it has no approved drugs on the market yet. It operates mainly in the United States and has worked with agencies like the U.S. Department of Defense and BARDA on programs targeting diseases such as COVID-19 and diabetes. Its core competitive advantage is its unique platform — using cattle as living antibody factories can produce large volumes faster than traditional methods — but the main risk is that the company must successfully advance drugs through clinical trials and win regulatory approval before it can generate meaningful commercial revenue.